Killing Targeted Bacteria With CRISPR Drugs Is SNIPR BIOME's Promise
CEO Says Danish Biotech Wants To Soon Raise $100-$150m
SNIPR BIOME aims to be the world’s top developer of CRISPR-based drugs that selectively target and kill bacteria, while leaving the rest of the patient’s microbiome intact, the biotech’s CEO tells Scrip.